Search research articles
Contact Us
Filters
Showing results (531-540 of 553) with videos related to
Page
of 56
Sort By:
Nature Genetics
|
June 1, 1996
Low incidence of BRCA2 mutations in breast carcinoma and other cancers
D H Teng, R Bogden, J Mitchell, et al.
Annals of Surgical Oncology
|
June 24, 2016
Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative
Jeffrey Landercasper, Lisa Bailey, Tiffany S Berry, et al.
The New England Journal of Medicine
|
January 6, 2000
Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses
G Mari, R L Deter, R L Carpenter, et al.
Annals of Surgical Oncology
|
November 24, 2017
Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters
Jeffrey Landercasper, Oluwadamilola M Fayanju, Lisa Bailey, et al.
Cancer Medicine
|
July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
Tommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Current Oncology (Toronto, Ont.)
|
April 25, 2015
Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014
S Ahmed, O Bathe, S Berry, et al.
Oncotarget
|
November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
Doreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 14, 2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
M Moore, S Gill, T Asmis, et al.
Plos One
|
July 30, 2021
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19
Donald A Berry, Andrew Ip, Brett E Lewis, et al.
Cancer Research
|
October 23, 1997
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor
D H Teng, W L Perry, J K Hogan, et al.
Page
of 56
Search research articles
Search
Showing results (531-540 of 553) with videos related to
Sort By:
Page
of 56
Nature Genetics
|
June 1, 1996
Low incidence of BRCA2 mutations in breast carcinoma and other cancers
D H Teng, R Bogden, J Mitchell, et al.
Annals of Surgical Oncology
|
June 24, 2016
Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative
Jeffrey Landercasper, Lisa Bailey, Tiffany S Berry, et al.
The New England Journal of Medicine
|
January 6, 2000
Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses
G Mari, R L Deter, R L Carpenter, et al.
Annals of Surgical Oncology
|
November 24, 2017
Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters
Jeffrey Landercasper, Oluwadamilola M Fayanju, Lisa Bailey, et al.
Cancer Medicine
|
July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
Tommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Current Oncology (Toronto, Ont.)
|
April 25, 2015
Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014
S Ahmed, O Bathe, S Berry, et al.
Oncotarget
|
November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
Doreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 14, 2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
M Moore, S Gill, T Asmis, et al.
Plos One
|
July 30, 2021
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19
Donald A Berry, Andrew Ip, Brett E Lewis, et al.
Cancer Research
|
October 23, 1997
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor
D H Teng, W L Perry, J K Hogan, et al.
Page
of 56